Tags

Type your tag names separated by a space and hit enter

Silica-lipid hybrid (SLH) versus non-lipid formulations for optimising the dose-dependent oral absorption of celecoxib.
Pharm Res. 2011 Sep; 28(9):2273-87.PR

Abstract

PURPOSE

To investigate the dose linearity of celecoxib (CEL) pharmacokinetics from various non-lipid and lipid-based formulations; to probe the mechanisms of CEL absorption from a nano-structured silica-lipid hybrid (SLH) microparticle dosage form.

METHODS

Single-dose pharmacokinetic parameters of CEL were determined in fasted rats at dose levels of 5, 20 and 50 mg/kg in aqueous suspensions of pure CEL, Celebrex® and CEL-SLH microparticles formulated using medium-chain lipids (Miglyol 812 or Capmul MCM) and Aerosil® silica nanoparticles. An in vitro lipolysis model was used to characterise the dynamic solubilisation state of CEL under digesting conditions.

RESULTS

CEL-SLH formulations and Celebrex® consistently produced a 2-fold higher maximum plasma concentration (C(max)) and bioavailability (AUC(0→∞)) than pure CEL in a dose-linear manner within the dose range of 5-50 mg/kg CEL (R² > 0.8). Lipolysis drug phase partition data indicate a 2.5-7.5-fold higher CEL solubilising capacity resulting from the digestion of SLH microparticles as compared to the simulated fasted state endogenous micelles. Strong correlations were obtained between maximum CEL solubilisation levels during lipolysis and in vivo pharmacokinetic parameters (R² > 0.9).

CONCLUSIONS

Collectively, the results highlight the potential of the SLH microparticles in enhancing the bioavailability of CEL in a dose-linear manner as facilitated by supersaturated solubilisation of CEL in the intestinal milieu.

Authors+Show Affiliations

Ian Wark Research Institute, ARC Special Research Centre for Particle and Material, Interfaces, University of South Australia, Mawson Lakes, SA 5095, Australia.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21560021

Citation

Tan, Angel, et al. "Silica-lipid Hybrid (SLH) Versus Non-lipid Formulations for Optimising the Dose-dependent Oral Absorption of Celecoxib." Pharmaceutical Research, vol. 28, no. 9, 2011, pp. 2273-87.
Tan A, Davey AK, Prestidge CA. Silica-lipid hybrid (SLH) versus non-lipid formulations for optimising the dose-dependent oral absorption of celecoxib. Pharm Res. 2011;28(9):2273-87.
Tan, A., Davey, A. K., & Prestidge, C. A. (2011). Silica-lipid hybrid (SLH) versus non-lipid formulations for optimising the dose-dependent oral absorption of celecoxib. Pharmaceutical Research, 28(9), 2273-87. https://doi.org/10.1007/s11095-011-0458-x
Tan A, Davey AK, Prestidge CA. Silica-lipid Hybrid (SLH) Versus Non-lipid Formulations for Optimising the Dose-dependent Oral Absorption of Celecoxib. Pharm Res. 2011;28(9):2273-87. PubMed PMID: 21560021.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Silica-lipid hybrid (SLH) versus non-lipid formulations for optimising the dose-dependent oral absorption of celecoxib. AU - Tan,Angel, AU - Davey,Andrew K, AU - Prestidge,Clive A, Y1 - 2011/05/11/ PY - 2011/01/20/received PY - 2011/02/23/accepted PY - 2011/5/12/entrez PY - 2011/5/12/pubmed PY - 2011/12/28/medline SP - 2273 EP - 87 JF - Pharmaceutical research JO - Pharm Res VL - 28 IS - 9 N2 - PURPOSE: To investigate the dose linearity of celecoxib (CEL) pharmacokinetics from various non-lipid and lipid-based formulations; to probe the mechanisms of CEL absorption from a nano-structured silica-lipid hybrid (SLH) microparticle dosage form. METHODS: Single-dose pharmacokinetic parameters of CEL were determined in fasted rats at dose levels of 5, 20 and 50 mg/kg in aqueous suspensions of pure CEL, Celebrex® and CEL-SLH microparticles formulated using medium-chain lipids (Miglyol 812 or Capmul MCM) and Aerosil® silica nanoparticles. An in vitro lipolysis model was used to characterise the dynamic solubilisation state of CEL under digesting conditions. RESULTS: CEL-SLH formulations and Celebrex® consistently produced a 2-fold higher maximum plasma concentration (C(max)) and bioavailability (AUC(0→∞)) than pure CEL in a dose-linear manner within the dose range of 5-50 mg/kg CEL (R² > 0.8). Lipolysis drug phase partition data indicate a 2.5-7.5-fold higher CEL solubilising capacity resulting from the digestion of SLH microparticles as compared to the simulated fasted state endogenous micelles. Strong correlations were obtained between maximum CEL solubilisation levels during lipolysis and in vivo pharmacokinetic parameters (R² > 0.9). CONCLUSIONS: Collectively, the results highlight the potential of the SLH microparticles in enhancing the bioavailability of CEL in a dose-linear manner as facilitated by supersaturated solubilisation of CEL in the intestinal milieu. SN - 1573-904X UR - https://www.unboundmedicine.com/medline/citation/21560021/Silica_lipid_hybrid__SLH__versus_non_lipid_formulations_for_optimising_the_dose_dependent_oral_absorption_of_celecoxib_ L2 - https://doi.org/10.1007/s11095-011-0458-x DB - PRIME DP - Unbound Medicine ER -